Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway
Identifieur interne : 000804 ( Main/Merge ); précédent : 000803; suivant : 000805Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway
Auteurs : Jie Zhu [République populaire de Chine] ; Ya Zheng [République populaire de Chine] ; Haiyan Zhang [République populaire de Chine] ; Yanmei Liu [République populaire de Chine] ; Hong Sun [République populaire de Chine] ; Pengnan Zhang [République populaire de Chine]Source :
- American Journal of Translational Research [ 1943-8141 ] ; 2019.
Abstract
Background: It has been reported that Galectin-1 (Gal-1) indicates bad prognosis of patients with ovarian cancer, and Gal-1 overexpression promotes metastasis of ovarian cancer cells. Nevertheless, the underlying mechanisms of the Gal-1-mediated enhancement of metastasis are still unclear. Furthermore, little is known about whether Gal-1 affects epithelial-mesenchymal transition (EMT) in ovarian cancer. Methods: The human SKOV3-ip and SKOV3 cell lines were transfected with Gal-1 siRNAs and LV-Gal-1 lentivirus, respectively. Cell migration and cell invasion abilities were examined by transwell assays. Protein or mRNA levels of Gal-1, p-JNK1/2, t-JNK1/2, p-p38, t-p38 and EMT markers were detected via immunohistochemistry, qRT-PCR and western blot in SKOV3-ip as well as SKOV3 cells. A xenograft tumour model was used in vivo to ascertain whether upregulation of Gal-1 in ovarian cancer cells can enhance metastasis in vivo. Results: In a total of 107 human ovarian cancer tissues, higher Gal-1 expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage, while lower E-cadherin expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage. In vitro assays revealed that Gal-1 promoted migration and invasion of ovarian cancer cells, as well as EMT. Additionally, the results showed that Gal-1 enhanced EMT, migration and invasion by activating the MAPK JNK/p38 signalling pathway. Moreover, in vivo bioluminescence imaging revealed that Gal-1 modulated ovarian cancer metastasis in nude mice. Immunochemistry of xenograft tumour tissues confirmed that Gal-1 may modulate metastasis and EMT via the MAPK JNK/p38 signalling pathway. Additionally, treatment of Gal-1 mice with the MAPK JNK/p38 signalling pathway antagonists SB203580 or SP600125 reduced cancer metastasis. Conclusion: Gal-1 enhances metastasis and EMT of ovarian cancer cells via promoting the activation of the MAPK JNK/p38 signalling pathway, suggesting the possibility that Gal-1 is a molecular target to prevent and cure ovarian cancer metastasis.
Url:
PubMed: 31312395
PubMed Central: 6614631
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000354
- to stream Pmc, to step Curation: 000354
- to stream Pmc, to step Checkpoint: 000745
- to stream Ncbi, to step Merge: 000810
- to stream Ncbi, to step Curation: 000810
- to stream Ncbi, to step Checkpoint: 000810
Links to Exploration step
PMC:6614631Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway</title>
<author><name sortKey="Zhu, Jie" sort="Zhu, Jie" uniqKey="Zhu J" first="Jie" last="Zhu">Jie Zhu</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zheng, Ya" sort="Zheng, Ya" uniqKey="Zheng Y" first="Ya" last="Zheng">Ya Zheng</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhang, Haiyan" sort="Zhang, Haiyan" uniqKey="Zhang H" first="Haiyan" last="Zhang">Haiyan Zhang</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Liu, Yanmei" sort="Liu, Yanmei" uniqKey="Liu Y" first="Yanmei" last="Liu">Yanmei Liu</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhang, Pengnan" sort="Zhang, Pengnan" uniqKey="Zhang P" first="Pengnan" last="Zhang">Pengnan Zhang</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">31312395</idno>
<idno type="pmc">6614631</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614631</idno>
<idno type="RBID">PMC:6614631</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000354</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000354</idno>
<idno type="wicri:Area/Pmc/Curation">000354</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000354</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000745</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000745</idno>
<idno type="wicri:Area/Ncbi/Merge">000810</idno>
<idno type="wicri:Area/Ncbi/Curation">000810</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000810</idno>
<idno type="wicri:Area/Main/Merge">000804</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway</title>
<author><name sortKey="Zhu, Jie" sort="Zhu, Jie" uniqKey="Zhu J" first="Jie" last="Zhu">Jie Zhu</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zheng, Ya" sort="Zheng, Ya" uniqKey="Zheng Y" first="Ya" last="Zheng">Ya Zheng</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhang, Haiyan" sort="Zhang, Haiyan" uniqKey="Zhang H" first="Haiyan" last="Zhang">Haiyan Zhang</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Liu, Yanmei" sort="Liu, Yanmei" uniqKey="Liu Y" first="Yanmei" last="Liu">Yanmei Liu</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sun, Hong" sort="Sun, Hong" uniqKey="Sun H" first="Hong" last="Sun">Hong Sun</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhang, Pengnan" sort="Zhang, Pengnan" uniqKey="Zhang P" first="Pengnan" last="Zhang">Pengnan Zhang</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases</institution>
<addr-line>Shanghai 200011, China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai 200011</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">American Journal of Translational Research</title>
<idno type="eISSN">1943-8141</idno>
<imprint><date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Background: It has been reported that Galectin-1 (Gal-1) indicates bad prognosis of patients with ovarian cancer, and Gal-1 overexpression promotes metastasis of ovarian cancer cells. Nevertheless, the underlying mechanisms of the Gal-1-mediated enhancement of metastasis are still unclear. Furthermore, little is known about whether Gal-1 affects epithelial-mesenchymal transition (EMT) in ovarian cancer. Methods: The human SKOV3-ip and SKOV3 cell lines were transfected with Gal-1 siRNAs and LV-Gal-1 lentivirus, respectively. Cell migration and cell invasion abilities were examined by transwell assays. Protein or mRNA levels of Gal-1, p-JNK1/2, t-JNK1/2, p-p38, t-p38 and EMT markers were detected via immunohistochemistry, qRT-PCR and western blot in SKOV3-ip as well as SKOV3 cells. A xenograft tumour model was used in vivo to ascertain whether upregulation of Gal-1 in ovarian cancer cells can enhance metastasis in vivo. Results: In a total of 107 human ovarian cancer tissues, higher Gal-1 expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage, while lower E-cadherin expression strongly associated with higher histological grade, more lymph node metastases and more advanced FIGO stage. In vitro assays revealed that Gal-1 promoted migration and invasion of ovarian cancer cells, as well as EMT. Additionally, the results showed that Gal-1 enhanced EMT, migration and invasion by activating the MAPK JNK/p38 signalling pathway. Moreover, in vivo bioluminescence imaging revealed that Gal-1 modulated ovarian cancer metastasis in nude mice. Immunochemistry of xenograft tumour tissues confirmed that Gal-1 may modulate metastasis and EMT via the MAPK JNK/p38 signalling pathway. Additionally, treatment of Gal-1 mice with the MAPK JNK/p38 signalling pathway antagonists SB203580 or SP600125 reduced cancer metastasis. Conclusion: Gal-1 enhances metastasis and EMT of ovarian cancer cells via promoting the activation of the MAPK JNK/p38 signalling pathway, suggesting the possibility that Gal-1 is a molecular target to prevent and cure ovarian cancer metastasis.</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000804 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000804 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Merge |type= RBID |clé= PMC:6614631 |texte= Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:31312395" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |